Health Care : Current Reviews

Effects of Nifedipine an antihypertensive drug on glucose and epinephrine

Joint Event on 9^th International Conference on Predictive, Preventive & Personalized Medicine & Molecular Diagnostics & 3^rd International Conference on Integrative Medicine & Alternative treatments

October 26-27, 2018 | Boston, USA

Ghulam Rasool Mashori

Peoples University of Medical and Health Sciences for Women, Pakistan

Scientific Tracks Abstracts: Health Care Current Reviews

Abstract:

Hypertension, hyperlipidemia, hyperglycemia and cigarette smoking are major risk factors for the development of Coronary Heart Diseases (Newcomer & Hennekens, 2007). Hypertension is the leading curable risk factor for cardiovascular disease, affecting more than 1 billion people worldwide (Patel et al., 2016). Treatment of hypertension is to reduce future cardiovascular morbidity and early death. Antihypertensive therapy has shown improvement in the incidences of stroke, heart failure & renal failure, however, the incidence of CHD has not been reduced to that degree (The Sprint Research Group, 2017). Normal human BP (Systolic/Diastolic) ranges from 120/80mmHg to 140/90mmHg. Hypertension is the continuous elevation of resting systolic ???140mmHg and diastolic ???90mmHg BP (Carretero & Operil, 2000). Effects of Nifedipine an antihypertensive drug were seen on glucose, insulin & epinephrine, in the light of Helsinki Criteria, a study designed on non-diabetic and diabetic hypertensive patients. Two sets, minimum of 12 patients (6-non-diabetics and 6-diabetics) were recruited for treatment. In set-A non-diabetic hypertensive patients were kept on placebo first for two weeks and GTT was performed, then patients switched on Nifedipine at an average dose of 23.8±7.4mg/day. When the diastolic BP normalized ???90mmHg at-least for 6-weeks period, then the second GTT was performed. In Set-B, diabetic hypertensive patients treated with Nifedipine first at an average dose 21.3±3.5mg/day for 6-weeks period, GTT was conducted, followed by a placebo period for 2-weeks then the patients went through the second GTT for quantifying glucose, insulin and catecholamine blood levels and results were compared. Based on results it is concluded that Nifedipine worsens glucose tolerance and it is a diabetogenic drug.

Biography :

Ghulam Rasool Mashori is working as Professor at Peoples University of Medical & Health Sciences for Women; Nawabshah, Pakistan, he supervises to Graduate & Postgraduates fellows. He after graduation acquired PhD (Pharmacology) in 1994 from the Faculty of Medicine, University Kebangsaan, Malaysia. He completed many Short/Long Courses and Training in Research areas of Health Sciences & Management Sciences. He has been involved in Teaching/Training to MBBS & PharmD students and Research/Supervisory works at MPhil & PhD levels with various Institutions i.e. Jinnah Postgraduate Medical Center, Karachi, Pakistan etc., produced many research fellows. Beside this he has experienced in Research, Quality Control & Administration with NIH, Islamabad, as Deputy Director General (Pharmacovigilance) and as Director, Central Drugs Laboratory with Ministry of Health, Government of Pakistan. He has supervisory experiences with reputed Pharma Industries. He holds Research, Managerial and Administrative skills. 38 research papers are on his credit published in reputed Journals. He is also Editorial/Review Board Member of various worlds’ reputed Journals. He delivered several talks on international forums in various conferences/workshops held in different countries like Pakistan, Malaysia, Hong Kong, Singapore, USA and Europe. His field of interest is Cardiovascular Pharmacology, Diabetes, Endocrinology, Neuropharmacology, Genetics etc.

E-mail: mashori286286@yahoo.com